Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011630 | 0.89 | ADORA2A (0.42) | ADORA3MAPTTP53KMT2ALMNA | |
| SCHEMBL940867 | 0.89 | KMT2A (0.43) | ADORA3MAPTTP53KMT2ALMNA | |
| SCHEMBL940803 | 0.88 | ADORA2A (0.41) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL5319229 | 0.88 | MAPT (0.42) | ADORA3MAPTTP53KMT2ALMNA | |
| SCHEMBL5254988 | 0.87 | ADORA3 (0.53) | ADORA3MAPTTP53KMT2ALMNA | |
| SCHEMBL29371671 | 0.87 | ADORA3 (0.53) | ADORA3MAPTTP53KMT2ALMNA | |
| SCHEMBL940828 | 0.87 | MAPT (0.43) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL939986 | 0.87 | THRB (0.44) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL941318 | 0.86 | MAPT (0.42) | MAPTTP53KMT2ALMNAMEN1 | |
| SCHEMBL940680 | 0.85 | ADORA2A (0.39) | MAPTTP53KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | claimed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | claimed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | claimed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096879-A9 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SYNTHELABO (FR) | 2003-11-20 | — | — | WO | claimed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | claimed |
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | US | disclosed |
| EP-1740580-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES , PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2007-01-10 | — | — | EP | disclosed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | disclosed |
| WO-2005100320-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | disclosed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096879-A9 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SYNTHELABO (FR) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SFPQ, ADRB3, KCNQ3 | ADORA3 1027/4885MAPT 1304/4885TP53 3256/4885 |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885MAPT 4760/4885TP53 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.